Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

222
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
222
Clinical Trials01:16

Clinical Trials

6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.8K
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

276
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
276
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

147
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
147
Hazard Ratio01:12

Hazard Ratio

155
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
155
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

178
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
178

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VEGF Is a Stronger Predictor of Depressive Symptoms than Other Inflammation Markers in People with HIV on Antiretroviral Therapy.

Viruses·2026
Same author

Design and Analysis of Randomized Clinical Trials With Average Hazard: Practical Guidance and Tools for Implementation.

Statistics in medicine·2026
Same author

Bereaved Caregiver Perspectives on Quality of Care at the End of Life Among Adolescents and Young Adults with Cancer.

Journal of palliative medicine·2026
Same author

Machine learning applied to echocardiographic deformation curves for prediction of heart failure and cardiovascular death.

International journal of cardiology·2026
Same author

Longitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy: A Secondary Analysis of a Cluster Randomized Clinical Trial.

JAMA network open·2026
Same author

Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention ('REVITALIZE') to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol.

BMC cancer·2026

Related Experiment Video

Updated: Jul 17, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

582

Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes.

Brian Lee Claggett1, Zachary R McCaw2, Lu Tian3

  • 1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston.

NEJM Evidence
|August 30, 2023
PubMed
Summary

A new model-free method estimates treatment effects using the area under the curve (AUC) of multiple outcomes. This approach, applied to heart failure hospitalizations and cardiovascular death, showed a 14% reduction in disease burden with combination therapy.

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
Detecting Behavioral Deficits in Rats After Traumatic Brain Injury
07:54

Detecting Behavioral Deficits in Rats After Traumatic Brain Injury

Published on: January 30, 2018

18.1K

Related Experiment Videos

Last Updated: Jul 17, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

582
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
Detecting Behavioral Deficits in Rats After Traumatic Brain Injury
07:54

Detecting Behavioral Deficits in Rats After Traumatic Brain Injury

Published on: January 30, 2018

18.1K

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Cardiovascular Research

Background:

  • Traditional methods for analyzing multiple event times in clinical trials rely on specific model assumptions.
  • Violations of these assumptions can lead to misleading treatment effect estimates.
  • There is a need for robust, model-free analytical procedures for better clinical interpretation.

Purpose of the Study:

  • To introduce and validate a robust, model-free method for analyzing time-to-event data with multiple outcomes.
  • To quantify treatment effects using the area under the curve (AUC) as a measure of cumulative disease burden.
  • To demonstrate the method's application and potential for improving clinical trial design.

Main Methods:

  • Calculated the area under the curve (AUC) for cumulative event counts over time in each treatment group.
  • Interpreted AUC as mean total event-free time lost, with higher AUC indicating worse outcomes.
  • Quantified treatment effect by the ratio or difference of AUCs between groups.

Main Results:

  • In the PARAGON-HF trial, AUCs for heart failure hospitalizations and cardiovascular death were 11.3 and 13.1 event-months for sacubitril/valsartan and valsartan, respectively.
  • The AUC ratio of 0.86 indicated a 14% reduction in disease burden favoring sacubitril/valsartan.
  • A future study designed with this method would require fewer patients than traditional time-to-first-event analyses.

Conclusions:

  • The proposed AUC method is robust, model-free, and provides a clinically interpretable summary of treatment effects over time.
  • This approach offers a valuable alternative for analyzing complex event data in clinical trials.
  • The method can inform more efficient study designs, potentially reducing patient recruitment numbers.